Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752524 | 0.86 | PTGS1 (0.36) | APPPTGS1PDE4ATP53LMNA | |
| SCHEMBL31710789 | 0.81 | ALDH1A1 (0.39) | APPPTGS1PDE4ATP53LMNA | |
| SCHEMBL9299683 | 0.79 | APP (0.35) | APP | |
| SCHEMBL329052 | 0.78 | APP (0.46) | APPPTGS1PDE4ATP53LMNA | |
| SCHEMBL25382857 | 0.76 | APP (0.44) | APPPTGS1PDE4ATP53LMNA | |
| Ammonia Solution, Strong SCHEMBL18008289 | 0.76 | APP (0.44) | APPPTGS1PDE4ATP53LMNA | |
| SCHEMBL966471 | 0.76 | APP (0.44) | APPPTGS1PDE4ATP53LMNA | |
| SCHEMBL5144485 | 0.76 | APP (0.44) | APPPTGS1PDE4ATP53LMNA | |
| SCHEMBL28621315 | 0.76 | APP (0.44) | APPPTGS1PDE4ATP53LMNA | |
| SCHEMBL25385302 | 0.76 | APP (0.44) | APPPTGS1PDE4ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-01-12 | — | — | US | disclosed |
| EP-3100728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9399067-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2429291-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-01-01 | — | — | US | disclosed |
| US-8835407-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8236782-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2429291-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CyDex Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132711-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | APP 867/4885PTGS1 217/4885PDE4A 47/4885 |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | APP 867/4885PTGS1 217/4885PDE4A 47/4885 |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | APP 867/4885PTGS1 217/4885PDE4A 47/4885 |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | P2RY6, GP6, PFKP | APP 867/4885PTGS1 217/4885PDE4A 47/4885 |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | APP 867/4885PTGS1 217/4885PDE4A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.